HBK Sorce Advisory LLC Reduces Stock Position in Pfizer Inc. (NYSE:PFE)

HBK Sorce Advisory LLC cut its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 19.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 113,133 shares of the biopharmaceutical company's stock after selling 26,759 shares during the period. HBK Sorce Advisory LLC's holdings in Pfizer were worth $3,001,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Retirement Wealth Solutions LLC purchased a new position in shares of Pfizer during the 4th quarter worth about $26,000. Rialto Wealth Management LLC purchased a new position in shares of Pfizer during the 4th quarter worth about $26,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Pfizer during the 4th quarter worth about $28,000. Gladius Capital Management LP boosted its stake in shares of Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 38,015 shares during the period. Finally, Noble Wealth Management PBC purchased a new position in shares of Pfizer during the 4th quarter worth about $31,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Down 1.0 %

NYSE PFE opened at $25.73 on Thursday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a market cap of $145.79 billion, a PE ratio of 18.24, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a 50 day moving average price of $26.28 and a 200 day moving average price of $27.18. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54.

Remove Ads

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer's revenue was up 24.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.10 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the business's stock in a transaction on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.06% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Truist Financial lowered their price objective on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, December 18th. UBS Group lowered their price objective on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research report on Wednesday, January 8th. Bank of America reissued a "neutral" rating and issued a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. StockNews.com cut shares of Pfizer from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, November 20th. Finally, Citigroup lowered their price objective on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Pfizer currently has an average rating of "Moderate Buy" and an average price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.